A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN-177 Treatment Over 28 Days in Patients With Secondary Hyperoxaluria and Kidney Stones
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2017
At a glance
- Drugs ALLN 177 (Primary)
- Indications Hyperoxaluria; Renal calculi
- Focus Therapeutic Use
- Sponsors Allena Pharmaceuticals
- 17 Jan 2017 Status changed from active, no longer recruiting to completed.
- 14 Dec 2016 Planned End Date changed from 1 Jul 2017 to 1 Apr 2017.
- 14 Dec 2016 Planned primary completion date changed from 1 May 2017 to 1 Feb 2017.